Seizure Management in the ICU
For seizures in the ICU, immediately administer benzodiazepines followed by non-sedating intravenous antiseizure medications (levetiracetam, valproate, or fosphenytoin), escalate to continuous infusions of midazolam or propofol for refractory cases, and obtain continuous EEG monitoring to detect nonconvulsive status epilepticus which is nearly universal in refractory cases. 1
Initial Management Algorithm
First-Line Treatment (0-5 minutes)
- Benzodiazepines immediately upon seizure recognition 2, 1
- Routes: IV, IM, buccal, intranasal, or rectal depending on access
- Do not delay for EEG confirmation in convulsive seizures
Second-Line Treatment (After benzodiazepine failure)
Administer ONE of the following non-sedating IV antiseizure medications 1:
- Levetiracetam (preferred in most ICU settings due to minimal drug interactions)
- Valproate
- (Fos)phenytoin
- Emerging alternatives: lacosamide or brivaracetam 1
The choice depends on patient factors including hepatic/renal function, age, and potential drug interactions 3. Critical caveat: Altered ICU physiology, renal replacement therapy, ECMO, and therapeutic hypothermia significantly affect drug levels and may cause therapeutic failure or toxicity 3.
Refractory Status Epilepticus (RSE)
If seizures continue despite benzodiazepines and second-line ASM, this is refractory SE 1. Mortality jumps from 10% in responsive cases to 25% in RSE 1.
Treatment for RSE:
- Continuous infusions of midazolam or propofol (most common) 1
- Alternative: Additional non-sedating ASMs before escalating to anesthetics 2
- Continuous video-EEG is mandatory at this stage—RSE is almost always nonconvulsive 1
Super-Refractory Status Epilepticus (SRSE)
SRSE occurs when seizures reemerge after weaning anesthetics or continue despite midazolam/propofol 1. Mortality approaches 40% 1.
Treatment escalation:
- Ketamine
- Barbiturates (pentobarbital, phenobarbital)
- Additional non-sedating ASMs 1
- Consider immunotherapy if autoimmune encephalitis suspected 1
EEG Monitoring Strategy
When to obtain EEG:
- Diagnostic phase: EEG required to reliably diagnose nonconvulsive SE (NCSE) 1
- Mandatory for RSE/SRSE management: Continuous video-EEG essential as these are almost always nonconvulsive 1
- High-risk patterns: Lateralized/generalized periodic discharges and lateralized rhythmic delta increase seizure risk 4
Clinical scenarios requiring EEG:
- Unexplained altered mental status post-seizure
- Persistent lethargy or subtle twitching 5
- Any patient not returning to baseline after convulsive activity
Special Considerations for ICU Seizures
Etiology-Driven Management
Rapidly identify underlying causes as this guides additional treatment 1:
- Underlying epilepsy
- Acute brain injury (trauma, cardiac arrest, stroke)
- Infections (meningitis, encephalitis)
- Metabolic derangements
- Medication side effects 5
If autoimmune encephalitis identified, immunotherapy is crucial 1.
Seizure Type Modifications 2
- Myoclonic seizures (idiopathic generalized epilepsy): Benzodiazepines preferred
- Focal motor seizures: May use slower administration rates and modulated dosing
- Continuous partial epilepsy: General anesthesia NOT indicated
- Complex partial SE: Exhaust multiple non-sedating ASMs (phenobarbital, valproate, levetiracetam) before general anesthesia 2
Critical Pitfalls to Avoid
Delayed treatment: Most significant factor in successful SE treatment is initiating ASMs immediately 5. Mortality and morbidity increase with treatment delays.
Missing NCSE: Nonconvulsive SE is more frequent than convulsive in ICU patients and carries high mortality if untreated 5. Maintain high suspicion in any patient with unexplained altered consciousness.
Ignoring altered pharmacokinetics: ICU patients have multiorgan failure, metabolic derangements, and interventions (RRT, ECMO, hypothermia) that dramatically alter drug levels 3. Standard dosing may fail or cause toxicity.
Inappropriate medication use: Do NOT prescribe benzodiazepines or ASMs for functional seizures without co-occurring epilepsy 6. Obtain video-EEG confirmation when diagnosis uncertain.
Polypharmacy interactions: Complex medication regimens in ICU patients create significant drug-drug interactions requiring multidisciplinary monitoring 3.
Duration of Treatment
- Early-onset ICU seizures (easily controlled): Limited treatment duration supported 7
- Late seizures: Higher epilepsy risk—treat for extended periods or indefinitely 7
- Refractory/super-refractory cases: Prolonged treatment necessary with gradual weaning under continuous EEG monitoring
Outcome Determinants
Mortality ranges 10-15% overall but varies significantly 1:
- Responsive SE: 10% mortality
- Refractory SE: 25% mortality
- Super-refractory SE: 40% mortality
Primary mortality drivers: increasing age, underlying etiology, medical comorbidities, and treatment refractoriness 1.